Regeneron and Sanofi Expand Antibody Alliance: $1B Upfront, $7B in Milestones, and Lawsuit Settlement
REGN sits 33% above its 52-week low of $541.
Summary
Regeneron and Sanofi expanded their antibody collaboration to co-develop four new long-acting immunology antibodies, with Sanofi paying $1.0 billion upfront and up to $7.0 billion in milestones. The deal also settles Regeneron's lawsuit over Dupixent commercialization information.
Key Events · M&A and Partnerships · REGN
-
Sixth Amendment Expands Antibody Collaboration
Regeneron and Sanofi agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting IL-13, IL-4, IL-4Rα, and a bispecific IL-4xIL-13.
-
$1B Upfront, $7B in Milestones
Sanofi will pay Regeneron $1.0 billion upfront, with up to $7.0 billion in additional development, regulatory, and commercial milestone payments. Global profits on New Licensed Products will be shared 50/50.
-
Lawsuit Settlement Removes Overhang
Regeneron agreed to dismiss its lawsuit concerning Sanofi's obligation to provide full access to Dupixent commercialization information and audit rights under the Antibody LCA.
-
Q3 IPR&D Charge of $22M
Regeneron expects a pre-tax acquired IPR&D charge of approximately $22 million in Q3 2026, reducing GAAP and non-GAAP EPS by approximately $0.18.
Analysis · REGN · Life Sciences
Regeneron formalized a major expansion of its 20-year Sanofi collaboration, adding four long-acting immunology antibodies with a $1.0 billion upfront payment and up to $7.0 billion in milestone payments. The deal also resolves a lawsuit over Dupixent commercialization information and audit rights. For a company with a $74.8 billion market cap, the $1B upfront is meaningful but not transformative; the real value lies in the milestone structure and the removal of litigation overhang. The expected $22 million IPR&D charge is immaterial to earnings.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.80%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REGN was trading at $721.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.8B. The 52-week trading range was $541.00 to $859.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.